Meeting
2019 Genitourinary Cancers Symposium
Optimizing the use of androgen deprivation therapy in men with localized intermediate risk prostate cancer in the era of modern dose-escalated radiation therapy.
Authors
Sagar Anil Patel
Winship Cancer Institute of Emory University, Atlanta, GA
Sagar Anil Patel , Kevin H. Nguyen , Alan K. Lee , David Jeffrey Demanes , Albert Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 109)
DOI
10.1200/JCO.2019.37.7_suppl.109
Abstract #
109
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
First Author: Jason W.D. Hearn
Poster
2016 ASCO Annual Meeting
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
First Author: Bernard M. Dubray
Poster
2015 ASCO Annual Meeting
A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.
First Author: Abdenour Nabid
Poster
2011 ASCO Annual Meeting
Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05.
First Author: A. Zapatero